Tokyo, June 11, 2007 (JCN Newswire) - Astellas Pharma Inc. and Pfizer Japan Inc. today announced that their selective COX-2 inhibitor Celecox(R)(generic name: celecoxib), a non-steroidal anti-inflammatory drug (NSAID), will become available in Japan on June 12, 2007, with the indication of “relief of inflammation and pain associated with rheumatoid arthritis (RA) and osteoarthritis (OA)”.
